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Abstract
Purpose: Gallium-68 (Ga-68)-labeled tracers for imaging expression of the prostate-specific
membrane antigen (PSMA) such as the [68Ga]Ga-PSMA-HBED-CC have already demonstrated
high potential for the detection of recurrent prostate cancer. However, compared to Ga-68, a
labeling with fluorine-18 (F-18) would offer advantages with respect to availability, production
amount, and image resolution. [18F]DCFPyL is a promising F-18-labeled candidate for PSMA-
positron emission tomography (PET) imaging that has been recently introduced. In the current
study, we aimed to compare [68Ga]Ga-PSMA-HBED-CC and [18F]DCFPyL for clinical use in
biochemically relapsed prostate cancer.
Procedures: In 14 selected patients with PSA relapse of prostate cancer, [18F]DCFPyL
PET/X-ray computed tomography (CT) was performed in addition to [68Ga]Ga-PSMA-
HBED-CC PET/CT. A systematic comparison was carried out between results obtained
with both tracers with regard to the number of detected PSMA-positive lesions, the
standardized uptake value (SUV)max and the lesion to background ratios.
Results: All suspicious lesions identified by [68Ga]Ga-PSMA-HBED-CC were also detected with
[18F]DCFPyL. In three patients, additional lesionswereobservedusing [18F]DCFPyLPET/CT. Themean
SUVmax in the concordant [
18F]DCFPyL PSMA-positive lesions was significantly higher as compared to
[68Ga]Ga-PSMA-HBED-CC (14.5 vs. 12.2, p=0.028, n=15). The mean tumor to background ratios (n=
15) were significantly higher for [18F]DCFPyL compared to [68Ga]Ga-PSMA-HBED-CC using kidney,
spleen, or parotid as reference organs (p=0.006, p=0.002, p=0.008), but no significant differences were
found using the liver (p=0.167) or the mediastinum (p=0.363) as reference organs.
Conclusion: [18F]DCFPyL PET/CT provided a high image quality and visualized small prostate
lesions with excellent sensitivity. [18F]DCFPyL represents a highly promising alternative to
[68Ga]Ga-PSMA-HBED-CC for PSMA-PET/CT imaging in relapsed prostate cancer.
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Introduction
The prostate-specific membrane antigen (PSMA) isoverexpressed on the cell surface of prostate cancer
(PC) cells [1]. Recent studies with gallium-68 (Ga-68)-
labeled Glu-NH-CO-NH-Lys-(Ahx) ([68Ga]Ga-PSMA-
HBED-CC) have shown the potential of this radioligand to
detect relapses and metastases of PC with improved contrast
when compared to [18F]fluoromethylcholine positron emission
tomography (PET)/X-ray computed tomography (CT) [2–5].
Additionally, iodine-124, iodine-131, and lutetium-177-labeled
PSMA ligands have been reported for dosimetric and therapeu-
tic use [6, 7]. Several PSMA inhibitors were developed which
compromise different pharmacophoric structures to interact
with the binding pocket for N-acetyl-L-aspartyl-L-glutamate.
PSMA-binding ligands are bound to the extracellular domain of
PSMA. However, the transmembranous location of the binding
domain and its enzyme activity enable the subsequent internal-
ization of these ligands. The prostate-specific membrane
antigen is also expressed in the tumor-associated neovasculature
of gastric and colorectal cancer [8, 9]. Thus, these PSMA-
selective ligands may be of interest for imaging other tumor
types in the future.
In comparison to currently broadly applied Ga-68-
labeled PSMA ligands, fluorine-18 (F-18)-labeled com-
pounds would offer some important advantages. This
includes not only an increase of the number of
examinations owing to the higher production capacity
but also an excellent image quality. The latter will be a
result of optimized tracer doses leading to high imaging
statistics and the decay properties of F-18 itself. F-18
exhibits a low positron emission energy of 0.6 MeV.
Therefore, the distance to decelerate the positron in
human tissue is much shorter in comparison to Ga-68
(β+-energy=2.3 MeV) resulting in a much higher image
resolution. Recently, Chen and colleagues [10] have
published first data on [18F]DCFPyL (2-(3-{1-carboxy-
5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ure-
ido)-pentanedioic acid), a new PSMA-selective ligand
with a high binding affinity for PSMA. It was suggested
that this compound may represent a highly promising
candidate for PET imaging of PSMA-overexpressing
tissues [10].
In this work, a comparison between [68Ga]Ga-PSMA-
HBED-CC and [18F]DCFPyL PET/CT in patients with a
PSA-relapse of prostate cancer was carried out.
We assumed that [18F]DCFPyL would bear the potential
of high diagnostic accuracy due to the following:
 Availability of higher tracer activity amounts in combi-
nation with the longer half-life of F-18, enabling imaging
at later time points resulting in higher clearance and lower
nonspecific binding
 Higher image quality due to lower positron emission
energy of F-18
We aimed to confirm and potentially extend the findings
obtained with our diagnostic standard, [68Ga]Ga-PSMA-
HBED-CC PET/CT, by adding a second scan with
[18F]DCFPyL, representing a different PSMA tracer. By
choosing this approach, we tried to collect accumulating
evidence in the diagnostic assessment of selected patients
and to compare the properties of [18F]DCFPyL with
[68Ga]Ga-PSMA-HBED-CC at the same time.
Materials and Methods
Patient Characteristics
In this study, 14 selected patients were included who underwent
both [68Ga]Ga-PSMA-HBED-CC PET/CT and [18F]DCFPyL PET/
CT with the aim to determine if one of the two tracers exhibits
better detection of recurrent prostate cancer and/or metastases. The
patients had biochemical relapse of prostate cancer after initial
curative treatment, either radical prostatectomy or radiation-based
therapy. All patients showed rising PSA level and suspected
progressive disease following prior treatment of prostate cancer.
In 11 patients, the PSA level had increased to more than 1 ng/ml.
All patients underwent the examination as part of their clinical
workup. Patients were selected for the dual-scan procedure
assuming that a thorough diagnostic assessment would have a
significant influence on their individual subsequent therapeutic
measures, i.e., local versus systemic therapy, indication for or
exclusion from surgical treatment or external beam radiation
therapy. This included, e.g., suspected false-negative or equivocal
PET/CT results, detection of a solitary metastasis, or oligometa-
static status potentially accessible for local therapy.
First, [68Ga]Ga-PSMA-HBED-CC PET/CT was performed,
representing the standard procedure at our center. Subsequently,
in 14 selected patients, additional [18F]DCFPyL PET/CT was
carried out within a period of 3 weeks following the first scan. All
patients underwent the examinations as part of the clinical workup
in order to accumulate diagnostic evidence and potentially optimize
their individual treatment. This study does not represent a
systematic clinical trial, comparing the clinical value of two
diagnostic instruments in a blinded fashion. All patients signed
informed consent regarding the scientific evaluation of their data.
Preparation of [68Ga]Ga-PSMA-HBED-CC
[68Ga]Ga-PSMA-HBED-CC was produced according to the meth-
ods reported by Eder et al. [11] and Schäfer et al. [12]. The whole
labeling procedure was carried out under good manufacturing
practice (GMP) conditions. For labeling, a 68Ge/68Ga-generator
(iThemba), distributed by IDB Holland BV (Baarle-Nassau, the
Netherlands), was used. After fractionated elution with 5 ml 0.6 M
HCl, 500 μl Ga-68 generator eluate were neutralized with 250 μl
2 M sodium acetate solution (in Ultrapur water, sterilized in 1 ml
aliquots). Then, 500 μl (5 μg in water, Ultrapur, Merck, Darmstadt,
Germany) of PSMA-HBED-CC (ABX, Radeberg, Germany; CA
index name: 4,6,12,19-tetraazadocosane-1,3,7-tricarboxylic acid,
22—[3-[[[2-[[[5-(2-carboxyethyl)-2-hydroxyphenyl] -methyl]
(carboxymethyl) amino] ethyl] (carboxymethyl) amino] methyl]-4-
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hydroxyphenyl]—5,13,20-trioxo-, (3S,7S)-, supplied as trifluoroa-
cetate salt) were added and mixed vigorously. The reaction mixture
was heated at 80 °C for 10 min. After 5 min cooling at room
temperature (RT), the solution was diluted with 8.75 ml sterile isotonic
saline. Two aliquots for quality controls (radiochemical purity and
endotoxin testing) were withdrawn. Radiochemical purity was
determined by reversed phase HPLC (WellChrom system, Knauer,
Berlin, Germany) with a Knauer Hypersil ODS (4 mm) column.
Endotoxin testing (LAL) was carried out on Endosafe MCS™ from
Charles River (Ecully, France) using their cartridges with a sensitivity
of 5.0–0.05 EU/ml. Samples were checked for sterility by the Institute
for Medical Microbiology, Immunology and Hygiene, University
Hospital Cologne. Labeling provided [68Ga]Ga-PSMA-HBED-CC in
high radiochemical purity (998 %). The specific activity of [68Ga]Ga-
PSMA-HBED-CC was 62 GBq/μmol.
In addition, the affinity-related IC50 values of the reaction
mixtures of both labeling conditions were determined on the PSMA
expressing cell line LNCaP. Indeed, both the RT-labeled fraction
and the 95 °C-labeled fraction bound PSMA with identical affinities
(IC50 values 27.4±1.3 and 24.8±1.2 nm, respectively) [13].
Preparation of [18F]DCFPyL
[18F]Fluoride was produced via the 18O (p,n)18F reaction by
bombardment of enriched [18O] water with 16.5 MeV protons
using a MC16 cyclotron (Scanditronix, Uppsala, Sweden) at the
Max Planck Institute for Metabolism Research.
The synthesis of [18F]DCFPyL was performed under GMP
conditions as previously reported by Chen et al. [10]. The
radiolabeled product was analyzed using the following conditions:
column: Chromolith SpeedROD®, 50×4.6 mm (Merck Millipore,
Darmstadt, Germany); eluent: 5 % EtOH in 0.38 % H3PO4 (pH 2);
flow rate: 3.0 ml/min; tR=2.2 min. The final product was formulated
in a PBS solution (pH 4–6). The formulated solution of
[18F]DCFPyL was tested for sterility and endotoxin content.
Production under GMP conditions provided [18F]DCFPyL in
reasonable radiochemical yields of 8–12 % and in high radiochem-
ical purity (998 %). The specific activity of [18F]DCFPyL
amounted to 72 GBq/μmol.
The PSMA enzyme inhibition potency of compound 3 was
determined with a modified Amplex Red glutamic acid assay after
incubation with the cell lysates of LNCaP cell extracts in the
presence of NAAG for 2 h at 37 °C. The enzyme inhibitory
constant (Ki) for compound 3 was 1.1±0.1 nmol/l, comparable with
that of ZJ-43, which was 1.4±0.2 nmol/l under same measurement
conditions. ZJ-43 is a urea-based potent inhibitor of NAAG and is
used as an internal reference in the assay.
Imaging
The mean dosage of 128.3 MBq±35.9 MBq [68Ga]Ga-PSMA-HBED-
CC solution was injected as an intravenous bolus. Variation of the
injected activity was caused by the variable elution efficiencies
obtained during the lifetime of the 68Ge/68Ga radionuclide generator.
The preparations contained 2.65 nmol PSMA ligand.
The mean dosage of 318.4 MBq±59.0 MBq [18F]DCFPyL
complex solution was injected as an intravenous bolus. The
variability of the injected dose of [18F]DCFPyL is explained by
the available activity after the production of [18F]DCFPyL and by
adaption to body weight. The preparations contained between 2.7
and 5.1 nmol (mean 4.0 nmol) PSMA ligand depending on the
dosage of [18F]DCFPyL.
Patients fasted for at least 4 h prior to injection of
[68Ga]Ga-PSMA-HBED-CC or [18F]DCFPyL. There were no
adverse effects observed in any of the patients after injection of
both tracers.
For both tracers, whole-body PET and a non-contrast-enhanced
(low-dose) CT scan were performed on a Biograph 16 PET/CT
scanner (Siemens, Erlangen, Germany) in eight patients and on a
Biograph mCT 128 scanner (Siemens, Erlangen, Germany) in six
patients 1 h post injection of the [68Ga]Ga-PSMA-HBED-CC and
2 h post injection of the [18F]DCFPyL, respectively. The time
window between injection and start of data acquisition was chosen
analogously to published data for [68Ga]Ga-PSMA-HBED-CC [2–
5] and for [18F]DCFPyL [14]. Attenuation correction was
performed using the low-dose non-enhanced CT data.
To ensure comparability between different PET/CT scanners,
reconstruction was performed via an OSEM algorithm (4 iterations
and 14 subsets), followed by an intrinsic 5-mm Gaussian filter in all
directions for the Biograph 16 True Point (Siemens Medical
Solutions), containing full-ring dedicated PET and 16-slice CT
instrumentation. When using the Biograph mCT Flow-Edge 128
PET/CT system (Siemens Medical Solutions) with a 128-slice
spiral CT, iterative reconstruction was performed using 4 iterations
and 12 subsets by an intrinsic 5-mm Gaussian filter.
Image Analysis
Image analysis was performed using an appropriate workstation
and software (Syngo TrueD, Siemens, Erlangen, Germany).
Clinical PET/CT reading was performed by three experienced
specialists from the department of nuclear medicine and from the
department of radiology in consensus in a side-by-side analysis of
the results obtained with both tracers. Lesions were visually
interpreted as suspicious for local relapse, lymph node metastasis,
bone metastasis, or visceral metastasis.
The standardized uptake value (SUV)max was measured in up to
three hottest lesions (as identified in the [68Ga]Ga-PSMA-HBED-CC
scan) and their counterpart in the [18F]DCFPyL scan. Background
SUVmean values were measured in a volume of interest (VOI) with
2 cm diameter in the liver, spleen, kidney, mediastinum, and parotid in
all patients. For the calculation of mean values and to compare the
SUVmax values of the lesions and their ratios, SPSS 22 was used.
Results
Patient characteristics are shown in Table 1.
Presence of PSMA-Positive Lesions
In 4 of the 14 patients (29 %), no PSMA-positive lesions
were detected with either [68Ga]Ga-PSMA-HBED-CC or
with [18F]DCFPyL. In 10 of 14 patients (71 %), at least one
lesion suspicious for prostate cancer tissue was detected in
[68Ga]Ga-PSMA-HBED-CC PET/CT imaging and in
[18F]DCFPyL PET/CT imaging. In 3 patients, at least one
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additional PSMA-positive lesion was detected with
[18F]DCFPyL PET/CT as compared to the [68Ga]Ga-PSMA
scan. Thus, all patients were classified accordingly with both
tracers regarding the general presence of a PSMA-positive
suspicious finding (yes/no). Eleven patients (79 %) would
also have been classified consistently with both tracers
regarding number and location of their lesions, and in 3
(21 %) of patients, additional lesions were detected with
[18F]DCFPyL.
Type and Location of Lesions
With respect to the type/location of suspicious lesions,
[68Ga]Ga-PSMA-HBED-CC PET/CT had detected 2 bone
metastases, and [18F]DCFPyL PET/CT had detected 5
putative bone metastases. [68Ga]Ga-PSMA-HBED-CC
PET/CT had detected 20 lymph node metastases, and
[18F]DCFPyL PET/CT had detected 26 putative lymph node
metastases. [68Ga]Ga-PSMA-HBED-CC PET/CT and
[18F]DCFPyL PET/CT were suspicious for local relapse in
4 cases each.
The additional suspicious lesions detected with
[18F]DCFPyL were found in the lumbar vertebra L2 in a
patients with bone metastases in the left humerus and the
right femur (patient 2), in a pelvic lymph node beyond the
vena cava inferior in a patient with a concordant left iliac
PSMA-positive lymph node metastasis (patient 7), and in
mediastinal, left cervical, left supraclavicular, left axillary
lymph nodes as well as in the thoracal vertebra Th3 and the
Table 1. Patient characteristics and pathological tracer uptake in [68Ga]Ga-PSMA-HBED-CC PET/CT and [18F]DCFPyL PET/CT. The preparations
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LN lymph node, LR local relapse, n.a. not available, RT radiotherapy, [68Ga]PSMA [68Ga]Ga-PSMA-HBED-CC PET/CT, [18F]PSMA [18F]DCFPyL PET/CT
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Fig. 1 Patient no. 12 with a rising PSA level of 3.87 ng/ml. In the past, the patient had retroperitoneal lymph node metastases,
which were irradiated. On a Biograph mCT 128 scanner, comparison between a MIP (maximum intensity projection) with
[18F]DCFPyL and b MIP with [68Ga]Ga-PSMA-HBED-CC. [18F]DCFPyL PET/CT clearly demonstrates several additional
supradiaphragmatic PSMA-positive lesions. [68Ga]Ga-PSMA-HBED-CC PET/CT showed the supradiaphragmal lesion in the
sternum.
Fig. 2 Patient no. 12, Biograph mCT 128. [18F]DCFPyL PET/CT (b) was suspicious of an additional lymph node metastasis in
the dorsal mediastinum, visible as a normal-sized lymph node in a low-dose CT scan without tracer accumulation on c
[68Ga]Ga-PSMA-HBED-CC PET/CT. d Low-dose CT in bone window and e [18F]DCFPyL PET/CT were suspicious of a bone
metastasis in vertebra Th3, barely detectable in f [68Ga]Ga-PSMA-HBED-CC PET/CT. h [18F]DCFPyL PET/CT was clearly
suspicious of bone metastasis in the processus xiphoideus sterni, hard to detect in g low-dose CT or i [68Ga]Ga-PSMA-HBED-
CC PET/CT.
M. Dietlein et al.: 18F-labeled PSMA-PET Imaging in Relapsed Prostate Cancer 579
sternal processus xiphoideus in a patient with concordant
PSMA-positive retroperitoneal lymph node metastases
(patient 12).
Verification of Lesions
The bone metastases in the lumbar vertebra L2 (patient
2) and in the thoracal vertebral Th3 (patient 12) were
confirmed by CT retrospectively. In patient 7, a
concordant left iliac PSMA-positive lymph node was
detected with both tracers and an additional F-18 PSMA-
positive pelvic lymph was reported. This patient under-
went surgical lymph node resection, and the left iliac
metastasis was confirmed histologically. The additional
pelvic metastasis was not detected by salvage lymph
node dissection, but PSA remained increased postopera-
tively, indicating that this lesion may have represented
the remaining PSA-producing tissue. In 1 patient, the
solitary PSMA spot in the irradiated prostate, seen in the
[68Ga]Ga-PSMA-HBED-CC PET/CT and in the
[18F]DCFPyL PET/CT, was not confirmed by core
biopsy (patient 4). In 1 patient, the concordant solitary
PSMA-avid lymph node metastasis was confirmed histo-
logically by systematic lymphadenectomy, while core
biopsy was negative for local relapse despite a focal
PSMA concentration within the irradiated prostate (pa-
tient 1). Examples of the PSMA-positive lesions are
shown in Figs. 1, 2, 3, and 4.
Quantitative Comparison
The mean SUVmax in the concordant PSMA-positive lesions
was 14.5 for [18F]DCFPyL and 12.2 for [68Ga]Ga-PSMA-
HBED-CC (p=0.028, n=15 metastases). The mean back-
ground SUVmean values for [
18F]DCFPyL and [68Ga]Ga-
PSMA-HBED-CC in all 14 patients examined were 6.2 and
5.1 in the liver (p=0.049), 4.9 and 7.2 in the spleen
(p=0.005), 19.6 and 31.7 in the kidney (p=0.001), 1.3 and
1.2 in the mediastinum (p=0.056, n.s.), and 10.9 and 12.9 in
the parotid (n=0.121, n.s.), respectively.
To compare the tumor/background contrast between the
two tracers, we calculated SUV values in suspicious lesions/
background in seven patients with maximum three lesions,
detectable with both PET procedures. This resulted in a
comparison of altogether 15 tumor/background ratios. Most
of the suspected lymph node/bone metastases showed a
higher SUV ratio for [18F]DCFPyL using the kidney
(Fig. 5a) or the spleen as a reference region, but no
significant difference was found when using for the liver
(Fig. 5b) or the mediastinum as reference organ. In detail,
the mean tumor to background ratios between the SUVmax in
the PSMA-avid lesions with [18F]DCFPyL and [68Ga]Ga-
PSMA-HBED-CC were 2.9 and 2.3 as compared with the
SUVmean in the liver (p=0.167, n.s.), 4.3 and 2.1 as
compared with the SUVmean in the spleen (p=0.002), 1.0
and 0.4 as compared with the SUVmean in the kidney (p=
0.006), 10.7 and 9.7 as compared with the SUVmean in the
mediastinum (p=0.363, n.s.), and 1.4 and 0.9 as compared
with the SUVmean in the parotid (p=0.008), respectively.
Clinical Consequences
In the majority of cases, [68Ga]Ga-PSMA-HBED-CC and
[18F]DCFPyL PET/CT resulted in accumulating evidence,
supporting further treatment decisions consistently. Both
imaging series accordingly supported decisions towards core
biopsy of the irradiated prostate in three patients, to local
therapy options (lymph node dissection or radiotherapy) in
four patients with one to two PSMA-positive lymph nodes
and to systematic therapy in three patients. In four patients,
neither imaging test detected a lesion explaining the rise in
PSA levels.
Fig. 3 Patient no. 2 with a rising PSA level of 4.7 ng/ml. a
Low-dose CT in bone window and b [18F]DCFPyL PET/CT
were suspicious of bone metastasis in vertebra L2, hard to
discern in the c [68Ga]Ga-PSMA-HBED-CC PET/CT. Imaging
was performed on a Biograph 16 PET/CT.
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[18F]DCFPyL PET/CT resulted in the detection of
additional vertebral bone metastases in two patients (patient
2 and 12) in an oligometastatic state (patient 2 showed bone
metastases also in [68Ga]Ga-PSMA-HBED-CC PET/CT but
to a lesser extent). This finding did not have immediate
therapeutical consequences because both patients were
asymptomatic at the time of their PET/CT examination.
However, more accurate knowledge on the extent of bone
metastases bears the potential to perform better targeted
radiotherapy in the future (i.e., if the patients become
symptomatic from their bone metastases). The detection of
many PSMA-positive supradiaphragmatic lymph nodes with
[18F]DCFPyL in addition to retroperitoneal lymph node
metastases also detected with [68Ga]Ga-PSMA-HBED-CC
supported the decision to omit local radiotherapy of the
retroperitoneal lymphatic pathways (patient 12). In one
patient, a second PSMA-avid lymph node in the upper
pelvis was detected with [18F]DCFPyL in addition to
another pelvic lymph node (detected with both tracers). In
this patient, systematic bilateral pelvic lymph node dissec-
tion was performed and not influenced by the [18F]DCFPyL
findings. Unfortunately, only the larger metastasis (positive
with both tracers) was detected intraoperatively and the
patient remained PSA positive after surgery (patient 7).
Discussion
We analyzed 14 patients who underwent both [68Ga]Ga-
PSMA-HBED-CC PET/CT and [18F]DCFPyL PET/CT. In
all cases, a rising PSA level indicated disease recurrence
following prior treatment of prostate cancer.
The following findings emerge from this analysis:
Y All suspicious lesions identified with [68Ga]Ga-PSMA-
HBED-CC were detected with [18F]DCFPyL consistently.
Y [18F]DCFPyL demonstrated a significantly higher SUV-
max as compared to [
68Ga]Ga-PSMA-HBED-CC in consistent
lesions and a better tumor to background ratio when the
kidney, spleen, or parotid was used as a reference organ.
The tumor to background ratio did not differ significantly
between [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC
when the liver or the mediastinum was used as a reference
organ. Although based on a small number of subjects,
these findings support the notion that [18F]DCFPyL
provides at least comparable tumor/background contrast
as observed with [68Ga]Ga-PSMA-HBED-CC.
Y Using [18F]DCFPyL, additional suspicious lesions plausi-
ble for further metastases were detected in 3/14 patients.
This indicates a high sensitivity of this tracer.
Fig. 4 Patient no. 7 with a rising PSA level to 1.3 ng/ml. In the past, the patient had left iliac lymph node dissection with
histologically confirmed lymph node metastases. Both tracers have shown a left iliac PSMA-avid lymph node, which was
confirmed as metastasis (a–c). Additionally, e the [18F]DCFPyL PET/CT was suspicious of a second PSMA-positive lymph node
below the bifurcation of the v. cava inferior, visible as a normal-sized lymph node on d CT, hard to detected on f [68Ga]Ga-
PSMA-HBED-CC PET/CT. a Low-dose CT scan, b [18F]DCFPyL PET/CT, and c [68Ga]Ga-PSMA-HBED-CC PET/CT at the level
of the iliacae communes._d Low-dose CT scan, e [18F]DCFPyL PET/CT, and f [68Ga]Ga-PSMA-HBED-CC PET/CT at the level
of the bifurcation. Imaging was performed on a Biograph 16 PET/CT.
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One explanation for the higher detection rate using
[18F]DCFPyL can be found in the higher injected dose,
which allowed later acquisition times, potentially leading to
better signal to noise ratios due to reduction of nonspecific
signal. Lower background activity has been observed for the
[18F]DCFPyL in some organs such as the kidney. Indepen-
dently from injected dose, faster clearance of the tracer from
non-target tissue and higher affinity, may potentially have
contributed to the detection of additional skeletal metastases
observed for [18F]DCFPyL as compared to [68Ga]Ga-
PSMA-HBED-CC.
It is important to notice that the higher detection rate for
PSMA-avid lymph nodes by [18F]DCFPyL was not
attributed to retroperitoneal PSMA foci, where the differen-
tiation against celiac ganglia (i.e., false-positive findings)
might be a question [15].
Radiolabeling with Ga-68 is an excellent alternative for
imaging centers with expertise in handling the commercially
available 68Ge/68Ga radionuclide generator but without own
(cost-intense) cyclotron. However, a single preparation (0.3–
0.6 GBq Ga-68) may only allow scanning up to two to four
patients and the output depends on the half-life of the
generator. As now established at our center, a single
radiolabeling procedure of [18F]DCFPyL resulted in a batch
containing 6 to 7 GBq of [18F]DCFPyL. This rendered it
possible to examine six patients after a single preparation
with an optimal dose, which represents an advantage for
Fig. 5 a Ratio of SUVmax in lesions to SUVmean in the kidney and b ratio of SUVmax in lesions to SUVmean in the liver. The blue
columns represent [68Ga]Ga-PSMA-HBED-CC PET/CT, and the red columns represent [18F]DCFPyL PET/CT. [18F]DCFPyL
showed a higher tumor to background ratio than [68Ga]Ga-PSMA-HBED-CC when the kidney was used as a reference organ
(p=0.006, n=15). The tumor to background ratio did not differ significantly between [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-
CC when the liver was used as a reference organ (p=0.167, n=15). LN lymph node metastasis, LR local relapse, BM bone
metastasis.
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centers with an own cyclotron and a production of F-18 in
the daily management. Furthermore, due to the longer half-
life of F-18 (110 vs. 68 min for Ga-68), it may also allow
transportation to remote sites from commercial vendors.
A limitation of the current study is the lack of a consistent
histological validation of [18F]DCFPyL findings. In princi-
ple, it cannot be excluded that additional lesions detected
with [18F]DCFPyL may represent false-positive findings.
However, particularly small PSMA-positive findings cannot
be easily confirmed histologically and it is impossible to
assess all lesions in patients with multiple metastases.
Generally, good correspondence between [18F]DCFPyL
and [68Ga]Ga-PSMA-HBED-CC findings was observed,
several lesions were confirmed histopathologically, and the
additional bone lesions detected with [18F]DCFPyL were
verified retrospectively by CT findings suspicious for bone
metastases. Thus, we believe that the high sensitivity of
[18F]DCFPyL, as indicated in the current study, appears
plausible. Nevertheless, the findings of the current study are
to be considered preliminary and the clinical performance of
[18F]DCFPyL will have to be further analyzed in the future.
Another limitation can be found in the selection of
patients. We did not recruit patients for both imaging series
prospectively, and the selected population cannot serve as a
representative sample. Due to the selection of patients with
complex clinical questions (several of them being negative
in [68Ga]Ga-PSMA-HBED-CC PET/CT), it might be possi-
ble that the diagnostic accuracy of [68Ga]Ga-PSMA-HBED-
CC PET/CT is underestimated.
Comparison of the two tracers has not been carried out
under identical conditions, i.e., mean injected dose and start
of acquisition have been higher respectively later for
[18F]DCFPyL, as compared to [68Ga]Ga-PSMA-HBED-CC
PET/CT. It cannot be excluded that the performance of
[68Ga]Ga-PSMA-HBED-CC PET/CT would have been more
similar to [18F]DCFPyL under more identical examination
conditions. However, it was the aim of this study to compare
the two tracers under the circumstances usually available in
clinical application. Generally, lower doses and earlier
acquisition periods p.i. are selected for 68Ga-labeled tracers.
The time period of 1 h between injection of [68Ga]Ga-
PSMA-HBED-CC and the start of PET/CT was reported by
many publications [2–5].
It was beyond the scope of an observational study to show
time-activity curves. The time period of 2 h between the
injection of [18F]DCFPyL and the start of data acquisition was
chosen in the light of conventional receptor imaging in nuclear
medicine using other tracers with contrast enhancement on
delayed images and is in accord with the data including time-
activity curves published by Szabo and colleagues [14]. Szabo
et al. have performed PET imaging at five different time points
and demonstrated a small number of lesions which became
visible only on PET-5 131–167 min p.i. The authors
recommended delayed imaging at 2 h [14]. We have not tested
different time periods between the injection of [18F]DCFPyL
and the start of data acquisition.
Independently from the radiolabeling with [18F] or
[68Ga], previous cancer therapies and low PSMA expression
caused by tumor heterogeneity [16, 17] might be responsible
for false-negative PET/CT results in some patients. We have
learned from other studies that imaging of the choline
transport and phosphorylation may detect PSMA-negative
metastases in some cases [2, 3]. Future studies should
investigate the diagnostic accuracy of F-18- or Ga-68-
labeled PSMA in the early PSA-relapse G1 ng/ml, when
[11C] or [18F] choline have low detection rates [18, 19] and
should redefine the therapeutic impact of PET/CT [20–22].
Improved diagnostic accuracy should be confirmed by
systematic comparison of sensitivity and specificity of both
agents.
Conclusion
Our results indicate that the [18F]-labeled compound
[18F]DCFPyL is a highly promising alternative to [68Ga]-
Ga-PSMA-HBED-CC for PSMA-PET/CT imaging in re-
lapsed prostate cancer. Based on significantly higher SUV
values in the PSMA-avid lesions, [18F]DCFPyL PET/CT
may represent a valuable tool to detect small prostate cancer
lesions with high sensitivity.
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